Kelun-Biotech Signs New Connected R&D Goods Supply Deal With China Resources Kelun

The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has entered into a new 2026 R&D-related Goods Framework Agreement with China Resources Kelun (Sichuan) Medicine Limited, covering the supply of R&D-related drugs, consumables and fixed assets, including clinical control samples, medical equipment and laboratory supplies, from 16 January 2026 to 31 December 2028. The agreement, which replaces a previous framework that expired at the end of 2025 and expands the scope to include fixed assets, is classified as a continuing connected transaction under Hong Kong listing rules due to China Resources Kelun’s association with a company director; when aggregated with an existing sales and distribution framework agreement, the transaction size remains small enough to require reporting and announcement but is exempt from independent shareholders’ approval, indicating ongoing operational integration with the connected party while posing limited regulatory and dilution risk to investors.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong–listed biopharmaceutical company focused on research and development, producing and supplying R&D-related drugs, consumables, medical equipment and laboratory supplies that support its pipeline and clinical activities in the healthcare sector.

Average Trading Volume: 646,244

Technical Sentiment Signal: Buy

Current Market Cap: HK$108.8B

For detailed information about 6990 stock, go to TipRanks’ Stock Analysis page.